Compounds > 2-hydroxyhemopyrroline-5-one

Page last updated: 2024-12-08

2-hydroxyhemopyrroline-5-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-hydroxyhemopyrroline-5-one: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	171278
MeSH ID	M0069295

Synonyms (16)

Synonym
3-ethyl-5-hydroxy-4,5-dimethyl-1h-pyrrol-2-one
4,5-dimethyl-3-ethyl-5-hydroxy-3-pyrrolin-2-one
hhp lactam
hydroxyhemopyrrolin-2-one
53573-42-5
2-hydroxyhemopyrroline-5-one
3-ethyl-5-hydroxy-4,5-dimethyl-pyrrolin-2-one
3-ethyl-5-hydroxy-4,5-dimethyl delta(3)-pyrrolin-2-one
hydroxyjhaemopyrrole lactam
2h-pyrrol-2-one, 3-ethyl-1,5-dihydro-5-hydroxy-4,5-dimethyl-
2-hydroxy-4-ethyl-2,3-dimethyl delta 3-pyrroline-5-one
alpha'-hydroxyhemopyrrol alpha-lactam
DTXSID90968347
4-ethyl-2,3-dimethyl-2h-pyrrole-2,5-diol
EN300-6505192
3-ethyl-5-hydroxy-4,5-dimethyl-2,5-dihydro-1h-pyrrol-2-one

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (28.57)	18.7374
1990's	1 (14.29)	18.2507
2000's	1 (14.29)	29.6817
2010's	1 (14.29)	24.3611
2020's	2 (28.57)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.50 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.80 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (33.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (66.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	1.95	1	0	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	4.49	7	0	pyrrole; secondary amine
kryptopyrrole kryptopyrrole: metabolite in schizophrenia	3.41	1	0
vitamin b 6 Vitamin B 6: VITAMIN B 6 refers to several PICOLINES (especially PYRIDOXINE; PYRIDOXAL; & PYRIDOXAMINE) that are efficiently converted by the body to PYRIDOXAL PHOSPHATE which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, and aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into PYRIDOXAMINE phosphate. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990). Most of vitamin B6 is eventually degraded to PYRIDOXIC ACID and excreted in the urine.	3.41	1	0
puerarin [no description available]	2.25	1	0	C-glycosyl compound; isoflavonoid

Condition	Indicated	Relationship Strength	Studies	Trials
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.25	1	0
Hepatocellular Carcinoma [description not available]	0	2.25	1	0
Cancer of Liver [description not available]	0	2.25	1	0
Invasiveness, Neoplasm [description not available]	0	2.25	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	2.25	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.25	1	0
Deficiency, Pyridoxine [description not available]	0	3.23	1	0
Porphyria [description not available]	0	3.82	4	0
Dementia Praecox [description not available]	0	3.61	3	0
Porphyrias A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of HEME in the LIVER, the BONE MARROW, or both. They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues.	0	3.82	4	0
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	0	3.61	3	0
Psychoses [description not available]	0	2.4	2	0
Aggression Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.	0	2.15	1	0
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	0	2.4	2	0
Diseases, Metabolic [description not available]	0	2.01	1	0
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	0	2.01	1	0
Poisoning, Lead [description not available]	0	1.95	1	0
Acute Disease Disease having a short and relatively severe course.	0	2.36	2	0
Lead Poisoning Poisoning that results from chronic or acute ingestion, injection, inhalation, or skin absorption of LEAD or lead compounds.	0	1.95	1	0